Purpose: In this paper, we report on the long-term therapeutic efficacy of maintenance treatment in 12 advanced renal carcinoma patients.
Patients and Methods: Following prior systemic treatment with 8-week cycles of subcutaneous interferon-α2a (s.c. IFN-α2a) and subcutaneous interleukin-2 (s.c. IL-2)-based immunotherapy (5-day standard Atzpodien regimen), patients received prolonged maintenance treatment consisting of intermittent s.c. IFN-α2a and s.c. IL-2, combined with long-term daily peroral 13-cis-retinoic acid (p.o. 13cRA).
Results: Patients received a mean of 10 months (range, 0–27 months) of maintenance treatment. Median progression-free survival was calculated at 6 months (range, 0–61 months), and median overall suvival was 22 months (range, 2–65 months) from the start of maintenance therapy. Of 12 patients, 5 were still alive (≥60 months) and 2 patients remained progression-free (61 months) at last follow-up. Maintenance treatment was well or moderately tolerated.
Conclusions: Maintenance treatment with s.c. IL-2/s.c. INF-α2a/p.o. 13-cRA may support long-term efficacy of prior s.c. IL-2/s.c. INF-α2a-based therapy in advanced renal carcinoma patients.
